Close
Xylem
Novotech

News

Speeding Up Toxicology Materials For Faster Drug Development

Quick delivery of toxicological materials According to Alejandro Fernandez Martell and James Berrie from Lonza, a bottleneck has developed in the supply of toxicological data to support INDs for novel therapies and, therefore, delivery of FIH studies, as a result...

Polycarbonate: A Crucial Material In Healthcare Solutions

Polycarbonate plastic, which is produced through the use of the well-studied, building-block chemistry known as Bisphenol A, or BPA, plays an important role in the field of healthcare and medical devices, particularly in hospitals, neonatal units, and surgical facilities....

Extractables & Leachables : Risks, Testing, And Innovations

Understanding the Impact of Extractables and Leachables (E&L) on Drug Safety Extractables and leachables (E&L) pose two primary risks: contamination from harmful impurities like nitrosamine or chromium, which can cause toxicity, and the reduction of drug efficacy due to destabilization...

TraceLink’s Magnum Release of Platform for Supply Chain Management

TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, has announced the Magnum release of its flagship platform, Opus, the only no-code network digitalization platform designed to democratize access to...

ArisGlobal Extends Collaboration with Sitero for Drug Development Technology Platform

ArisGlobal, an innovative technology company at the forefront of life sciences and creator ofโ€ฏLifeSphereยฎ, and Sitero LLC, a next-generation clinical trial solutions provider, today announced an expansion of their strategic partnership. This collaboration integrates Sitero's unified eClinical technology platform...

Radiopharmaceuticals : Rapid Growth And Rising Investments

The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field. Recent mergers, purchases, and joint deals...

GSKs Lung Cancer ADC Earns FDA Breakthrough Designation

The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year. The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป